Reconnect with yoga Tuesdays

People with PI who infuse CUVITRU® [Immune Globulin Subcutaneous (Human)] 20% Solution weekly or every other week may be able to experience more of these moments.

Shield icon.

Proven protection from infection.

CUVITRU is a primary immunodeficiency (PI) treatment that offers protection from infection* and a flexible treatment schedule that can be tailored to fit your lifestyle.1

*CUVITRU was studied in 77 people with primary immunodeficiency (PI) ≥2 years of age, with the main goal of measuring how many acute serious bacterial infections (ASBIs) were experienced over the course of 1 year. ASBIs are short-term but serious infections that require immediate medical care. For an immunoglobulin (IG) treatment to be effective, the rate of ASBIs must be <1 per year. On average, people taking CUVITRU experienced 0.012 ASBIs per year, which is significantly less.

Clinical study icon.

There was a low rate of local side effects, regardless of how fast or how much was infused.1

98.2%

of infusions (4247/4327) in the clinical study had no side effects at the infusion site*

Also known as local side effects and include pain, itching, and redness. The 1.8% of infusions that resulted in a side effect at the infusion site were mild or moderate. Infusion site side effects generally go away within a few hours and are less likely after the first few infusions.1 CUVITRU can be infused at a volume of up to 60 mL per site and at a rate of up to 60 mL per hour, per site.

A mild side effect causes temporary discomfort that goes away on its own, or with little medical intervention. A moderate side effect causes a slight decline in function that goes away on its own, or with little medical intervention, and has no further consequences. 2 of every 3 people (51 of 74) had no local side effects. The most common local ARs reported in ≥5% of patients were pain (20.3%), erythema (10.8%), and pruritus (5.4%).

What are the rates? What were the infusion times?

Starting infusion rate

10-20

mL/hour/site

You’ll infuse your first 2 infusions at 10 to 20 mL/hour/site. After that, you'll be able to increase your rate to 60 mL/hr/site, as tolerated.1

Average infusion time

0.95

 hours

(range, 0.2-6.4 hours) in a study of 77 people with PI ≥2 years old.1

CUVITRU was studied in 77 people with primary immunodeficiency (PI) ≥2 years of age, with the main goal of measuring how many acute serious bacterial infections (ASBIs) were experienced over the course of 1 year. ASBIs are short-term but serious infections that require immediate medical care.

Find safety information here.

This is where you’ll find important safety info, including the warning about blood clots, to consider when starting and monitoring your treatment with CUVITRU.

Cell phone icon.

Ready to reconnect?

Our Doctor Discussion Guide is an interactive Q&A to help start the conversation with your doctor and find out if CUVITRU administration is right for you.

Here for you every step of the way.

We have resources that help you get real, honest, helpful guidance should you ever need it, including co-pay assistance if you’re eligible.

At a minimum to be eligible, patients must have commercial insurance. Other terms and conditions apply.

Reference

1. CUVITRU. Prescribing Information, Takeda Pharmaceuticals USA Inc.; 2023.